Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages 676-677

  Brusselle, Guy G ^a,b   Provoost, Sharen ^a   Maes, Tania ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; FEVIPIPRANT; LONG ACTING DRUG; OC 000459; PLACEBO; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN D2 RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SETIPIPRANT; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR;

ALLERGIC ASTHMA; ASTHMA; BRONCHUS BIOPSY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EOSINOPHILIA; EOSINOPHILIC ASTHMA; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; INNATE IMMUNITY; MAINTENANCE THERAPY; NOTE; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BLOCKING; RESPIRATORY TRACT INFLAMMATION; TREATMENT RESPONSE; LOEFFLER PNEUMONIA;

ASTHMA; HUMANS; PULMONARY EOSINOPHILIA; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

EID: 84989812429     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30201-6     Document Type: Note

References (11)

1. 1 Wenzel, SE, Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18 (2012), 716–725.
2. 2 Braido, F, Brusselle, G, Guastalla, D, et al. Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIAISON) study. Respir Res 17 (2016), 1–10.
3. 3 Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
4. 2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med, 2016 published online August 5. http://dx.doi.org/10.1016/S2213-2600(16)30179-5.
5. 5 Balzar, S, Fajt, ML, Comhair, SAA, et al. Mast cell phenotype, location, and activation in severe asthma. Am J Respir Crit Care Med 183 (2011), 299–309.
6. 2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol, 131, 2013, 1504 12.e12.
7. 7 Singh, D, Cadden, P, Hunter, M, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J 41 (2013), 46–52.
8. 8 Diamant, Z, Sidharta, PN, Singh, D, et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 44 (2014), 1044–1052.
9. 9 Erpenbeck, VJ, Popov, TA, Miller, D, et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther, 2016 10.1016/j.pupt.2016.06.005 published online June 21.
10. 10 Brusselle, GG, Maes, T, Bracke, KR, Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 19 (2013), 977–979.
11. 11 Smith, SG, Chen, R, Kjarsgaard, M, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol 137 (2015), 75–86.e8.